Sunday, Remegen Announced A Clinical Research And Supply Agreement With Innovent Biologics To Explore Combination Therapies Of Antibody-drug Conjugates With Tyvyt (Sintilimab); Tyvyt Is Developed Collaboratively By Innovent & Eli Lilly
Portfolio Pulse from Benzinga Newsdesk
Remegen has announced a clinical research and supply agreement with Innovent Biologics to explore combination therapies of antibody-drug conjugates with Tyvyt (Sintilimab). Tyvyt is developed collaboratively by Innovent and Eli Lilly.
July 10, 2023 | 9:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly, as a collaborator in the development of Tyvyt, could potentially benefit from the clinical research agreement between Remegen and Innovent Biologics.
Eli Lilly's involvement in the development of Tyvyt means that any advancements or positive outcomes from the clinical research agreement could potentially enhance the drug's market position and, in turn, benefit Eli Lilly.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70